PLGA nanoparticles help bypass these mechanisms by enhancing intracellular drug accumulation, enabling ligand-mediated active targeting (e.g., EpCAM, CD44), and triggered drug release within the tumor microenvironment. The gene discussed is CD44; the disease is neoplasm.